Pharsight

1. Elestrin patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7470433	MYLAN SPECIALITY LP	Formulations for transdermal or transmucosal application	Aug, 2021 (2 years ago)
US7198801	MYLAN SPECIALITY LP	Formulations for transdermal or transmucosal application	Jun, 2022 (1 year, 9 months ago)

Market Authorisation Date: 15 December, 2006

Treatment: NA

Dosage: GEL, METERED;TRANSDERMAL

Strength	Dosage	Availability
0.06% (0.87GM/ACTIVATION)	GEL, METERED;TRANSDERMAL	Prescription

ELESTRIN family patents

2. Evamist patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6818226	PADAGIS US	Dermal penetration enhancers and drug delivery systems involving same	Feb, 2017 (7 years ago)
US6923983	PADAGIS US	Transdermal delivery of hormones	Feb, 2017 (7 years ago)
US6299900	PADAGIS US	Dermal penetration enhancers and drug delivery systems involving same	Feb, 2017 (7 years ago)
US6978945	PADAGIS US	Dispensing device	Jul, 2022 (1 year, 8 months ago)

Market Authorisation Date: 27 July, 2007

Treatment: Female hormone replacement therapy for postmenopausal women

Dosage: SPRAY;TRANSDERMAL

Strength	Dosage	Availability
1.53MG/SPRAY	SPRAY;TRANSDERMAL	Prescription

EVAMIST family patents

3. Imvexxy patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP19163006A	2022-09-22	Dr. Schön, Neymeyr & Partner Patentanwälte mbB	Granted and Under Opposition
EP19163006A	2022-09-21	Rieck, Markus	Granted and Under Opposition
EP12850845A	2022-03-09	Dr. Schön, Neymeyr & Partner Patentanwälte mbB	Granted and Under Opposition
EP12850845A	2022-03-09	Rieck, Markus	Granted and Under Opposition
EP12850845A	2022-03-09	Generics [UK] Limited	Granted and Under Opposition
EP13807188A	2022-01-14	Rieck, Markus	Revoked
EP13807121A	2019-12-23	Rieck, Markus	Revoked

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10835487	MAYNE PHARMA	Vaginal inserted estradiol pharmaceutical compositions and methods	Nov, 2032 (8 years from now)
US11246875	MAYNE PHARMA	Vaginal inserted estradiol pharmaceutical compositions and methods	Nov, 2032 (8 years from now)
US10537581	MAYNE PHARMA	Vaginal inserted estradiol pharmaceutical compositions and methods	Nov, 2032 (8 years from now)
US9289382	MAYNE PHARMA	Vaginal inserted estradiol pharmaceutical compositions and methods	Nov, 2032 (8 years from now)
US11304959	MAYNE PHARMA	Vaginal inserted estradiol pharmaceutical compositions and methods	Nov, 2032 (8 years from now)
US11497709	MAYNE PHARMA	Vaginal inserted estradiol pharmaceutical compositions and methods	Nov, 2032 (8 years from now)
US11351182	MAYNE PHARMA	Vaginal inserted estradiol pharmaceutical compositions and methods	Nov, 2032 (8 years from now)
US10806697	MAYNE PHARMA	Vaginal inserted estradiol pharmaceutical compositions and methods	Nov, 2032 (8 years from now)
US11241445	MAYNE PHARMA	Vaginal inserted estradiol pharmaceutical compositions and methods	Nov, 2032 (8 years from now)
US10568891	MAYNE PHARMA	Vaginal inserted estradiol pharmaceutical compositions and methods	Jun, 2033 (9 years from now)
US10668082	MAYNE PHARMA	Vaginal inserted estradiol pharmaceutical compositions and methods	Jun, 2033 (9 years from now)
US10888516	MAYNE PHARMA	Soluble estradiol capsule for vaginal insertion	Jun, 2033 (9 years from now)
US11123283	MAYNE PHARMA	Soluble estradiol capsule for vaginal insertion	Jun, 2033 (9 years from now)
US10471072	MAYNE PHARMA	Vaginal inserted estradiol pharmaceutical compositions and methods	Jun, 2033 (9 years from now)
US11116717	MAYNE PHARMA	Soluble estradiol capsule for vaginal insertion	Jun, 2033 (9 years from now)
US11065197	MAYNE PHARMA	Soluble estradiol capsule for vaginal insertion	Jun, 2033 (9 years from now)
US10258630	MAYNE PHARMA	Vaginal inserted estradiol pharmaceutical compositions and methods	Dec, 2033 (9 years from now)
US10398708	MAYNE PHARMA	Vaginal inserted estradiol pharmaceutical compositions and methods	Dec, 2033 (9 years from now)
US9180091	MAYNE PHARMA	Soluble estradiol capsule for vaginal insertion	Dec, 2033 (9 years from now)
US11266661	MAYNE PHARMA	Vaginal inserted estradiol pharmaceutical compositions and methods	Feb, 2034 (9 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	May 29, 2021

Market Authorisation Date: 29 May, 2018

Treatment: Treatment of a symptom of vulvar and vaginal atrophy; Treatment of dyspareunia; Treatment of moderate to severe dyspareunia

Dosage: INSERT;VAGINAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
4 mcg and 10 mcg	30 Dec, 2019	1		20 Dec, 2033

Strength	Dosage	Availability
0.01MG	INSERT;VAGINAL	Prescription
0.004MG	INSERT;VAGINAL	Prescription

IMVEXXY family patents

4. Menostar patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5891868	BAYER HLTHCARE	Methods for treating postmenopausal women using ultra-low doses of estrogen	Nov, 2017 (6 years ago)
US6692763	BAYER HLTHCARE	Methods for treating postmenopausal women using ultra-low doses of estrogen	Nov, 2017 (6 years ago)

Market Authorisation Date: 08 June, 2004

Treatment: Prevention of postmenopausal osteoporosis

Dosage: SYSTEM;TRANSDERMAL

Strength	Dosage	Availability
0.014MG/24HR	SYSTEM;TRANSDERMAL	Prescription

MENOSTAR family patents

5. Minivelle patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP09790211A	2016-03-23	3M Innovative Properties Company	Revoked

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US9833419	May, 2018	Terminated-Settled	Noven Pharmaceuticals, Inc.	Mylan Technologies, Inc.
US9724310	December, 2017	Terminated-Settled	Noven Pharmaceuticals, Inc.	Mylan Technologies, Inc.
US9730900	December, 2017	Terminated-Settled	Noven Pharmaceuticals, Inc.	Mylan Technologies, Inc.

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6024976	NOVEN	Solubility parameter based drug delivery system and method for altering drug saturation concentration	Jan, 2014 (10 years ago)
US5656286	NOVEN	Solubility parameter based drug delivery system and method for altering drug saturation concentration	Aug, 2014 (9 years ago)
US5646286	NOVEN	Palladium catalyzed vinylic substitution reactions with 2-substituted-pyridines	Aug, 2014 (9 years ago)
US9724310	NOVEN	Transdermal estrogen device and delivery	Jul, 2028 (4 years from now)
US8231906	NOVEN	Transdermal estrogen device and delivery	Jul, 2030 (6 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6841716	NOVEN	Patch	Apr, 2020 (3 years ago)
US9730900	NOVEN	Transdermal estrogen device and delivery	Jul, 2028 (4 years from now)
US9833419	NOVEN	Transdermal estrogen device and delivery	Jul, 2028 (4 years from now)

Market Authorisation Date: 23 September, 2014

Treatment: A method for administering estradiol comprising a monolithic transdermal drug delivery system consisting of (i) a backing layer and (ii) a single adhesive polymer matrix layer as claimed in us patent ...

Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.0375 mg/day 0.05 mg/day 0.075 mg/day 0.1 mg/day	18 Aug, 2014	1	15 Aug, 2018	04 Jul, 2030	Deferred
0.025 mg/day	08 May, 2015	1	15 Aug, 2018	04 Jul, 2030	Deferred

Strength	Dosage	Availability
0.075MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription
0.0375MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription
0.1MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription
0.05MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription
0.025MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription

MINIVELLE family patents

6. Vagifem patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP01270333A	2012-08-08	Helm AG	Revoked
EP01270333A	2012-08-01	Laboratorios Léon Farma, S.A.	Revoked

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5860946	NOVO NORDISK INC	Instrument for inserting a suppository	Jul, 2017 (6 years ago)
US7018992	NOVO NORDISK INC	Hormone composition	Sep, 2022 (1 year, 7 months ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Dosing Schedule(D-122)	Nov 25, 2012

Market Authorisation Date: 25 November, 2009

Treatment: Treatment of atrophic vaginitis due to menopause

Dosage: TABLET;VAGINAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
10 mcg	02 Jan, 2013	1	29 May, 2015	17 Sep, 2022	Eligible

Strength	Dosage	Availability
10MCG	TABLET;VAGINAL	Prescription

VAGIFEM family patents

7. Vivelle-dot patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5474783	SANDOZ	Solubility parameter based drug delivery system and method for altering drug saturation concentration	Dec, 2012 (11 years ago)
US5958446	SANDOZ	Solubility parameter based drug delivery system and method for altering drug saturation concentration	Dec, 2012 (11 years ago)
US6024976	SANDOZ	Solubility parameter based drug delivery system and method for altering drug saturation concentration	Jan, 2014 (10 years ago)
US5656286	SANDOZ	Solubility parameter based drug delivery system and method for altering drug saturation concentration	Aug, 2014 (9 years ago)

Market Authorisation Date: 03 May, 2002